Rozelixizumab for the treatment of myasthenia gravis

Rozanolixizumab (Rozanolixizumab) is a monoclonal antibody targeting FcRn (neonatal Fc receptor). In recent years, it has shown significant clinical potential in the treatment of myasthenia gravis. The drug, sold under the trade name RYSTIGGO, has been approved in Europe, the United States and other countries for the treatment of adult gMG patients who are positive for anti-acetylcholine receptor antibodies (AChR antibodies) or anti-muscle-specific tyrosine kinase antibodies (MuSK antibodies).

Compared with traditional therapies, roselixizumab is a biological agent with a novel mechanism, convenient administration, and relatively high safety. It is especially suitable for patients who have insufficient response to or intolerance to standard immunosuppressants. In actual clinical applications, roselixizumab is only used for subcutaneous injection and is not suitable for intravenous infusion, which is different from many traditional immunotherapy drugs.

The recommended standard usage is to calculate the dosage according to the patient's weight, and inject once a week for 6 consecutive weeks as a complete treatment cycle. The injection dose and infusion volume also vary according to different weight ranges: 420 mg (3 ml) is recommended for patients weighing less than 50 kg, 560 mg (4 ml) for those weighing between 50 and 100 kg, and 840 mg (6 ml) for patients weighing more than 100 kg. These doses should be infused slowly subcutaneously via an infusion pump by a healthcare professional at a recommended infusion rate of no more than 20 ml per hour to improve tolerability and reduce the risk of injection site discomfort.

Before initiating roselixizumab treatment, a vaccination evaluation should be performed to ensure that the patient has received the necessary vaccines before being in an immunosuppressed state, such as influenza vaccine, herpes zoster vaccine, or pneumococcal vaccine. The purpose of this preventive measure is to avoid an increased risk of infection due to a decrease in immune IgG during treatment. In addition, after the completion of each treatment cycle, whether a new course of treatment needs to be started should be determined by the doctor based on a comprehensive evaluation based on clinical manifestations, severity of myasthenia, IgG levels, and functional scores. There is currently insufficient data to confirm the safety of repeated use of roselixizumab within 63 days after the start of the last course of treatment, so it is recommended that the interval between courses should comply with the instructions in the instructions.

Reference materials:https://www.drugs.com/rystiggo.html